| For: | Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573 [PMID: 41368118 DOI: 10.4254/wjh.v17.i11.112573] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i11/112573.htm |
| Number | Citing Articles |
| 1 |
Sally Ibrahim Hassanein. MASLD biomarker discovery: evaluating lipidomics techniques across disease progression. Molecular Biology Reports 2026; 53(1) doi: 10.1007/s11033-026-11447-0
|
| 2 |
Tianyu Zhang, Yu Yuan, Chunli Lin, Chao Song, Tianrong Liao, Yuewen Sun, Hongzhen Tang, Inbakandan Dhinakarasamy. Environmental PFOA exposure and the risk of metabolic dysfunction-associated steatotic liver disease: An integrated computational toxicology and multi-omics study. PLOS One 2026; 21(9) doi: 10.1371/journal.pone.0357970
|
| 3 |
Shikha Gorke, Saloni Sharma, Afia Malik, Irfan Ahmad Wani
and Sheikh Tasduq Abdullah. Fibroblast - Function and Disease Mechanisms [Working Title]. 2026; doi: 10.5772/intechopen.1015589
|